Marty Makary: The FDA’s Quiet Blockade on Safer Nicotine

Key Takeaways

• Youth e‑cigarette use fell to 5.2% in past month
• Nicotine pouch use among teens is about 1.7%
• FDA under Marty Makary has stalled approvals for low‑risk products
• Blockade pushes consumers to illicit market, delaying harm reduction

Pulse Analysis

Evidence from public‑health researchers and government studies now places non‑combustible nicotine products—vapes, heated tobacco and nicotine pouches—at the bottom of the risk ladder compared with cigarettes. Youth vaping rates have collapsed from their 2020 peak to roughly 5.2% for any use in the past month, and frequent use (20+ days) is a fraction of that. Nicotine‑pouch experimentation among teenagers sits near 1.7%, indicating that the crisis narrative that once drove stringent controls has largely dissipated. This shift creates a commercial opening for manufacturers to capture adult smokers seeking reduced‑risk alternatives, a market projected to grow double‑digit annually.

Yet the FDA’s Center for Tobacco Products, led by Commissioner Marty Makary, has effectively placed a moratorium on new product approvals. Insiders suggest Makary’s hesitation stems less from scientific uncertainty than from personal legacy concerns; authorizing novel products could later be framed as a regulatory misstep. By keeping the pipeline closed, the agency forces consumers toward an existing illicit vape ecosystem that lacks quality controls, exposing users to unknown contaminants while forfeiting tax revenue and public‑health gains. The stalled approvals also impede tobacco‑industry players that have invested heavily in next‑generation products, slowing innovation and market entry.

The broader implications are stark. Continued reliance on combustible cigarettes sustains one of the nation’s leading causes of preventable death, while the illicit market expands unchecked. For investors and public‑health advocates, the signal is clear: regulatory certainty is essential to unlock the economic and health benefits of harm‑reduction products. A shift in FDA leadership or a structural reform that decouples product risk from blanket tobacco regulation could re‑ignite approval pathways, allowing legal, lower‑risk nicotine options to displace smoking and generate sizable market growth.